Japan's Ono Pharmaceutical gears up sales reps for Opdivo

Osaka-based Ono Pharmaceutical is gearing up its sales force to boost sales of Opdivo (nivolumab) as sales look set to pick up quickly from ¥2.5 billion ($21 million) at the end of March 2015 to past ¥100 billion annually in the coming years, Nikkei Asian Review reports. The drug is also sold by Bristol-Myers Squibb ($BMY), which acquired the originator company, Medarex. Ono secured Japan rights under a 2005 pact with Medarex; it has been approved there for unresectable melanoma since 2014. Nikkei said that the two companies now have a total of 300 sales reps aimed at around 1,000 key hospitals in Japan. Earlier this month, Ono said it would develop a new diagnostic tool to determine whether more patients will benefit from Opdivo. In April of last year, Ono filed for in-country approval of Opdivo to treat NSCLC and received manufacturing and marketing approval in December 2015. Report

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.